Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$845.38
+0.0%
$735.35
$623.78
$937.00
$799.56B0.474.11 million shs1.35 million shs
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$59.12
-0.9%
$54.73
$45.05
$120.56
$263.52B0.6812.16 million shs6.08 million shs
Sanofi stock logo
SNY
Sanofi
$49.31
-0.8%
$48.20
$44.62
$60.12
$120.87B0.512.74 million shs894,725 shs
Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
+0.59%+16.52%+16.39%+8.67%-4.71%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
-0.01%+7.47%+8.20%-14.30%-48.17%
Sanofi stock logo
SNY
Sanofi
-2.34%+8.89%+6.90%+3.18%-10.38%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$845.38
+0.0%
$735.35
$623.78
$937.00
$799.56B0.474.11 million shs1.35 million shs
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$59.12
-0.9%
$54.73
$45.05
$120.56
$263.52B0.6812.16 million shs6.08 million shs
Sanofi stock logo
SNY
Sanofi
$49.31
-0.8%
$48.20
$44.62
$60.12
$120.87B0.512.74 million shs894,725 shs
Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
+0.59%+16.52%+16.39%+8.67%-4.71%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
-0.01%+7.47%+8.20%-14.30%-48.17%
Sanofi stock logo
SNY
Sanofi
-2.34%+8.89%+6.90%+3.18%-10.38%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.64
Moderate Buy$938.9411.07% Upside
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
2.50
Moderate Buy$77.5031.09% Upside
Sanofi stock logo
SNY
Sanofi
3.00
Buy$62.6727.09% Upside

Current Analyst Ratings Breakdown

Latest NVO, SNY, and LLY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/3/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$1,028.00 ➝ $1,023.00
10/1/2025
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
HSBC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$70.00
10/1/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
HSBC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price Target$700.00 ➝ $800.00
10/1/2025
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
Hsbc Global Res
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHoldStrong-Buy
10/1/2025
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
HSBC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHoldBuy$70.00
9/29/2025
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeOverweightUnderweight$59.00 ➝ $47.00
9/29/2025
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong SellHold
9/27/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold (C+)
9/27/2025
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold (C-)
9/27/2025
Sanofi stock logo
SNY
Sanofi
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold (C)
9/17/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Berenberg Bank
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuyHold$970.00 ➝ $830.00
(Data available from 10/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$45.04B17.76$14.33 per share59.00$15.03 per share56.25
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$311.94B0.85$3.87 per share15.28$4.66 per share12.69
Sanofi stock logo
SNY
Sanofi
$44.46B2.72$5.16 per share9.55$33.20 per share1.49
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$10.59B$15.3055.2227.171.1725.91%92.72%16.89%10/30/2025 (Estimated)
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$14.64B$3.6416.2112.692.6335.60%78.64%24.51%11/5/2025 (Estimated)
Sanofi stock logo
SNY
Sanofi
$6.02B$4.1611.8310.381.2421.47%16.86%9.63%10/24/2025 (Estimated)

Latest NVO, SNY, and LLY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
10/30/2025Q3 2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.42N/AN/AN/A$16.09 billionN/A
10/24/2025Q3 2025
Sanofi stock logo
SNY
Sanofi
$1.65N/AN/AN/A$12.62 billionN/A
8/7/2025Q2 2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$5.59$6.31+$0.72$6.29$14.40 billion$15.56 billion
8/6/2025Q2 2025
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$0.93$0.97+$0.04$0.91$77.51 billion$11.69 billion
7/31/2025Q2 2025
Sanofi stock logo
SNY
Sanofi
$0.96$0.90-$0.06$1.84$9.91 billion$11.34 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.000.71%N/A39.22%11 Years
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$0.821.39%N/A22.53%N/A
Sanofi stock logo
SNY
Sanofi
$1.603.24%N/A38.46%N/A

Latest NVO, SNY, and LLY Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
8/6/2025
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
semi-annual$0.41192.4%8/18/20258/18/20258/26/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
1.86
1.28
1.00
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.52
0.78
0.56
Sanofi stock logo
SNY
Sanofi
0.19
1.27
0.94

Institutional Ownership

CompanyInstitutional Ownership
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
11.54%
Sanofi stock logo
SNY
Sanofi
14.04%

Insider Ownership

CompanyInsider Ownership
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.14%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.07%
Sanofi stock logo
SNY
Sanofi
1.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
47,000946.46 million945.13 millionOptionable
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
77,3494.47 billion4.46 billionOptionable
Sanofi stock logo
SNY
Sanofi
82,8782.46 billion2.43 billionOptionable

Recent News About These Companies

UBS Reaffirms Their Buy Rating on Sanofi (SNYNF)
Leerink Partnrs Has Negative Outlook for Sanofi Q4 Earnings
Matauro LLC Invests $1.85 Million in Sanofi $SNY
Sanofi (NASDAQ:SNY) Hits New 1-Year Low - Here's Why
12 Best Widow and Orphan Stocks to Buy According to Analysts

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Eli Lilly and Company stock logo

Eli Lilly and Company NYSE:LLY

$845.38 +0.33 (+0.04%)
As of 01:04 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Novo Nordisk A/S stock logo

Novo Nordisk A/S NYSE:NVO

$59.12 -0.53 (-0.89%)
As of 01:04 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Sanofi stock logo

Sanofi NASDAQ:SNY

$49.31 -0.40 (-0.81%)
As of 01:04 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.